AU
UK
CA
NZ
IND
US
Last update at 2025-04-14T13:56:27.560148Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -80.70200M | 3.38M | -23.40700M | -12.26300M | -13.51500M |
| Minority interest | - | - | - | - | - |
| Net income | -82.34000M | 2.06M | -23.87700M | -12.34800M | -30.77000M |
| Selling general administrative | 45.92M | 32.95M | 31.51M | 24.03M | 21.00M |
| Selling and marketing expenses | 106.95M | 76.76M | 52.77M | 71.11M | 58.42M |
| Gross profit | 139.83M | 133.10M | 75.77M | 98.16M | 80.38M |
| Reconciled depreciation | 2.62M | 1.34M | 1.39M | 1.55M | 1.21M |
| Ebit | -38.19000M | -1.28600M | -22.82800M | -12.06400M | -13.39200M |
| Ebitda | -38.00000M | 0.06M | -21.43400M | -10.51600M | -12.18300M |
| Depreciation and amortization | 0.19M | 1.34M | 1.39M | 1.55M | 1.21M |
| Non operating income net other | -39.45400M | - | -0.57900M | -0.19900M | -0.12300M |
| Operating income | -38.19000M | -1.28600M | -22.82800M | -12.06400M | -13.39200M |
| Other operating expenses | 290.59M | 229.44M | 170.51M | 193.78M | 176.11M |
| Interest expense | 5.66M | 2.51M | 0.58M | 0.20M | 0.88M |
| Tax provision | 1.64M | 1.32M | 0.47M | 0.09M | 17.25M |
| Interest income | 2.60M | - | - | 0.20M | 0.12M |
| Net interest income | -4.41300M | -3.22400M | -0.57900M | -0.19900M | -0.12300M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 1.64M | 1.32M | 0.47M | 0.09M | 17.25M |
| Total revenue | 252.40M | 231.27M | 147.68M | 181.71M | 162.72M |
| Total operating expenses | 178.02M | 131.28M | 98.60M | 110.23M | 93.77M |
| Cost of revenue | 112.57M | 98.17M | 71.91M | 83.55M | 82.34M |
| Total other income expense net | -42.51200M | 4.67M | -0.57900M | -0.19900M | -0.12300M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -82.34000M | 2.06M | -23.87700M | -12.34800M | -30.77000M |
| Net income applicable to common shares | -82.34000M | 2.06M | -23.87700M | -12.34800M | -30.77000M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 346.29M | 520.99M | 280.29M | 132.73M | 113.74M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 4.04M | 24.04M | 14.54M | 8.78M | 5.65M |
| Total liab | 518.12M | 536.17M | 223.72M | 75.85M | 67.80M |
| Total stockholder equity | -171.83000M | -15.18100M | 56.57M | 56.88M | 45.94M |
| Deferred long term liab | - | - | 4.20M | 3.40M | 3.39M |
| Other current liab | 54.23M | 57.45M | 54.10M | 32.30M | 32.31M |
| Common stock | 0.02M | 0.02M | 0.02M | 0.02M | 0.01M |
| Capital stock | 0.02M | 0.02M | 0.02M | 0.02M | 0.01M |
| Retained earnings | -303.34600M | -140.51300M | -58.17300M | -60.23500M | -36.35800M |
| Other liab | - | 1.69M | 1.33M | 1.75M | 3.48M |
| Good will | 1.34M | 1.34M | 1.34M | 1.34M | 1.34M |
| Other assets | 0.00000M | 15.21M | 11.65M | 22.80M | 6.83M |
| Cash | 143.61M | 145.92M | 164.16M | 47.05M | 26.32M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 87.75M | 105.84M | 73.90M | 50.73M | 55.85M |
| Current deferred revenue | 10.42M | 11.84M | 9.49M | 9.49M | 10.83M |
| Net debt | 288.30M | 284.70M | -14.01900M | -21.65200M | -18.40400M |
| Short term debt | 3.27M | 2.81M | 2.42M | 2.26M | 0.02M |
| Short long term debt | - | - | - | 3.63M | - |
| Short long term debt total | 431.91M | 430.62M | 150.15M | 25.39M | 7.91M |
| Other stockholder equity | 131.50M | 125.41M | 114.72M | 117.10M | 82.35M |
| Property plant equipment | - | 53.20M | 17.65M | 19.38M | 2.82M |
| Total current assets | 269.19M | 451.24M | 249.66M | 106.30M | 95.05M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | -16.52000M | 55.23M | 55.54M | 45.94M |
| Short term investments | 0.00000M | 171.39M | 74.05M | 0.00000M | 7.61M |
| Net receivables | 49.43M | 45.56M | 31.45M | 21.96M | 21.56M |
| Long term debt | 418.69M | 416.46M | 134.24M | 7.18M | - |
| Inventory | 72.10M | 63.63M | 39.50M | 28.51M | 33.92M |
| Accounts payable | 19.83M | 33.74M | 7.89M | 6.68M | 12.69M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | -0.09400M | -0.01100M | - | -0.06000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.02M | - | 0.02M | 0.01M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -140.51300M | - | -60.23500M | -36.35800M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 27.86M | 14.62M | 10.87M | 5.08M | 6.41M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 77.11M | 69.75M | 30.63M | 26.44M | 18.69M |
| Capital lease obligations | 11.33M | 14.16M | 15.90M | 18.21M | 7.91M |
| Long term debt total | - | - | - | - | 0.58M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | 137.43M | -194.18200M | -0.94400M | 6.39M | 2.01M |
| Change to liabilities | - | 26.93M | 0.80M | -9.01900M | 9.78M |
| Total cashflows from investing activities | - | -194.18200M | -0.94400M | 6.39M | 1.07M |
| Net borrowings | - | 246.34M | 137.79M | 6.63M | -0.64900M |
| Total cash from financing activities | -2.56800M | 242.94M | 117.53M | 31.30M | 1.41M |
| Change to operating activities | - | -17.45500M | 6.56M | -6.66800M | 0.74M |
| Net income | -162.83300M | -82.34000M | 2.06M | -23.87700M | -12.34800M |
| Change in cash | -3.01200M | -18.24000M | 117.82M | 20.73M | 0.26M |
| Begin period cash flow | 146.62M | 164.86M | 47.05M | 26.32M | 26.05M |
| End period cash flow | 143.61M | 146.62M | 164.86M | 47.05M | 26.32M |
| Total cash from operating activities | -137.87000M | -66.99500M | 1.24M | -16.95600M | -2.21700M |
| Issuance of capital stock | - | 0.00000M | 0.00000M | 28.80M | - |
| Depreciation | 10.72M | 2.62M | 1.34M | 1.39M | 1.55M |
| Other cashflows from investing activities | - | - | - | 0.03M | 0.04M |
| Dividends paid | - | 56.68M | 13.37M | 3.43M | 2.06M |
| Change to inventory | 15.57M | -34.99900M | -10.93600M | 5.41M | -5.90700M |
| Change to account receivables | -4.94000M | -15.90000M | -9.57400M | -2.55000M | -2.50900M |
| Sale purchase of stock | -3.29700M | -56.68000M | -16.13400M | -3.42800M | -0.83100M |
| Other cashflows from financing activities | -3.29700M | 343.19M | 131.36M | 6.44M | -0.83100M |
| Change to netincome | - | 51.52M | 8.41M | 15.87M | 10.58M |
| Capital expenditures | 33.01M | 22.70M | 1.01M | 1.28M | 0.99M |
| Change receivables | - | -15.90000M | - | -2.55000M | -2.50900M |
| Cash flows other operating | - | -15.46300M | - | -2.89100M | -4.72900M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | -18.24000M | - | 20.73M | 0.26M |
| Change in working capital | -11.19900M | -42.04900M | -10.86000M | -11.37200M | -4.91500M |
| Stock based compensation | 8.06M | 14.40M | 13.17M | 10.11M | 9.83M |
| Other non cash items | 51.10M | 40.19M | -4.34800M | 7.01M | 3.63M |
| Free cash flow | -170.88000M | -89.69300M | 0.22M | -18.23500M | -3.20800M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CUTR Cutera Inc |
- -% | - | - | - | 0.21 | 61.48 | 1.28 | -3.1112 |
| ABT Abbott Laboratories |
-0.58 0.66% | 87.83 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| SYK Stryker Corporation |
-3.11 1.01% | 304.69 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
-0.07 0.09% | 79.27 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
-0.96 2.12% | 44.33 | 31.49 | 17.24 | 4.41 | 3.65 | 4.88 | 19.19 |
Cutera, Inc. provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform. It also offers truSculpt, a high-powered radio frequency system designed for circumferential reduction, lipolysis, and deep tissue heating and treat all skin types; Secret RF, a fractional RF microneedling device that delivers heat into the deeper layers of the skin using controlled RF energy; and Enlighten SR/III, a laser platform with a dual wavelength for multi-colored tattoo removal, and the treatment of benign pigmented lesions and acne scars. In addition, the company provides Excel HR, a hair removal solution for all skin types; xeo, a multi-application platform for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity; and Secret DUO, two dual non-ablative fractional technologies that can be used individually or in combination to target a variety of aesthetic concerns and skin conditions on all skin types with little to no downtime. Further, it offers its products through direct sales and services, and network of distributors and direct international sales. Cutera, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.
3240 Bayshore Boulevard, Brisbane, CA, United States, 94005
| Name | Title | Year Born |
|---|---|---|
| Mr. J. Daniel Plants | Exec. Chairman | 1967 |
| Mr. David H. Mowry | CEO & Director | 1962 |
| Mr. Rohan R. Seth | Chief Financial Officer | 1978 |
| Dr. Michael A. Karavitis Ph.D. | Exec. VP & Chief Technology Officer | 1970 |
| Mr. Charles G. Thier | Chief Information Officer | 1963 |
| Anne Werdan | Director of Investor Relations | NA |
| Dr. Michael A. Karavitis Ph.D. | Executive VP & Chief Technology Officer | 1970 |
| Mr. Taylor C. Harris | President, CEO & Director | 1976 |
| Mr. Stuart Drummond | Interim Chief Financial Officer | NA |
| Mr. Jeffrey S. Jones | Chief Operating Officer | 1956 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...